Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
01 03 2022
Historique:
pubmed: 13 10 2021
medline: 3 3 2022
entrez: 12 10 2021
Statut: ppublish

Résumé

Little is known about the epidemiology of ventilator-acquired pneumonia among coronavirus disease 2019 patients such as incidence or etiological agents. Some studies suggest a higher risk of ventilator-associated pneumonia in this specific population. Cohort exposed/nonexposed study among the REA-REZO surveillance network. Multicentric; ICUs in France. The coronavirus disease 2019 patients at admission were matched on the age, sex, center of inclusion, presence of antimicrobial therapy at admission, patient provenance, time from ICU admission to mechanical ventilation, and Simplified Acute Physiology Score II at admission to the patients included between 2016 and 2019 within the same surveillance network (1:1). None. The overall incidence of ventilator-associated pneumonia, the cumulative incidence, and hazard rate of the first and the second ventilator-associated pneumonia were estimated. In addition, the ventilator-associated pneumonia microbiological ecology and specific resistant pattern in coronavirus disease 2019 exposed and nonexposed patients were compared. Medication data were not collected. A total of 1,879 patients were included in each group. The overall incidence of ventilator-associated pneumonia was higher among coronavirus disease 2019 exposed patients (25.5; 95% CI [23.7-27.45] vs 15.4; 95% CI [13.7-17.3] ventilator-associated pneumonia per 1,000 ventilation days). The cumulative incidence was higher for the first and the second ventilator-associated pneumonia among the coronavirus disease 2019 exposed patients (respective Gray test p < 0.0001 and 0.0167). The microbiological ecology and resistance were comparable between groups with a predominance of Enterobacterales and nonfermenting Gram-negative bacteria. The documented resistance pattern was similar between groups, except for a lower rate of methicillin-resistant Staphylococcus aureus in the coronavirus disease 2019 exposed patient (6% vs 23%; p = 0.013). There was a higher incidence of ventilator-associated pneumonia occurring among coronavirus disease 2019 patient compared with the general ICU population, with a similar microbiological ecology and resistance pattern.

Identifiants

pubmed: 34637422
doi: 10.1097/CCM.0000000000005297
pii: 00003246-202203000-00010
pmc: PMC8855761
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

449-459

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Déclaration de conflit d'intérêts

Dr. Vanhems’ institution received funding from Anios; he received funding from Astellas and Sanofi. Drs. Vanhem and Friggeri received funding from Pfizer. Dr. Friggeri received funding from MSD. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Références

Docherty AB, Harrison EM, Green CA, et al.; ISARIC4C Investigators: Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: Prospective observational cohort study. BMJ. 2020; 369:m1985
Kaeuffer C, Hyaric CL, Fabacher T, et al.: Clinical characteristics and risk factors associated with severe COVID-19: Prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. Eurosurveillance. 2020; 25:2000895
Vanhems P, Gustin MP, Elias C, et al.; COVID-Outcomes-HCL Consortium: Factors associated with admission to intensive care units in COVID-19 patients in Lyon-France. PLoS One. 2021; 16:e0243709
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators: Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: A prospective cohort study. Intensive Care Med. 2021; 47:60–73
Gamberini L, Tonetti T, Spadaro S, et al.: Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: Multicenter observational study in fifteen Italian ICUs. J Intensive Care. 2020; 8
Martin-Loeches I, Povoa P, Rodríguez A, et al.; TAVeM study: Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): A multicentre, prospective, observational study. Lancet Respir Med. 2015; 3:859–868
Melsen WG, Rovers MM, Groenwold RHH, et al.: Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013; 13:665–71
Bekaert M, Timsit JF, Vansteelandt S, et al.; Outcomerea Study Group: Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis. Am J Respir Crit Care Med. 2011; 184:1133–1139
Curcio D, Ferreira Cabrera L, Duarte A, et al.: Ventilator-associated pneumonia in patients with 2009 pandemic influenza A (H1N1) infection: An observational study. J Chemother Florence Italy. 2010; 22:428–30
Jain S, Benoit SR, Skarbinski J, et al.; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team: Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus--United States, 2009. Clin Infect Dis. 2012; 54:1221–1229
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al.; Dutch-Belgian Mycosis Study Group: Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir Med. 2018; 6:782–792
Luyt CE, Bouadma L, Morris AC, et al.: Pulmonary infections complicating ARDS. Intensive Care Med. 2020; 46:2168–2183
Safdar N, Crnich CJ, Maki DG: The pathogenesis of ventilator-associated pneumonia: Its relevance to developing effective strategies for prevention. Respir Care. 2005; 50:725–739
Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with COVID-19—Preliminary report. N Engl J Med. 2020; 384:693–704
Tomazini BM, Maia IS, Cavalcanti AB, et al.; COALITION COVID-19 Brazil III Investigators: Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA. 2020; 324:1307–1316
Rouzé A, Martin-Loeches I, Povoa P, et al.: Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: A European multicenter cohort study. Intensive Care Med. 2021; 47:188–198
Maes M, Higginson E, Pereira-Dias J, et al.: Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care. 2021; 25:25
Blonz G, Kouatchet A, Chudeau N, et al.: Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: A multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021; 25:72
Knaus WA, Draper EA, Wagner DP, et al.: APACHE II: A severity of disease classification system. Crit Care Med. 1985; 13:818–829
EUCAST: Comité de l’antibiogramme de la Société Francaise de Microbiologie. 2020
Plachouras D, Lepape A, Suetens C: ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units. Intensive Care Med. 2018; 44:2216–2218
Ho DE, Imai K, King G, et al.: Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007; 15:199–236
R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2017
Fauvernier M, Roche L, Uhry Z, et al.: Multi-dimensional penalized hazard model with continuous covariates: Applications for studying trends and social inequalities in cancer survival. J R Stat Soc Ser C Appl Stat. 2019; 68:1233–1257
Papazian L, Klompas M, Luyt CE: Ventilator-associated pneumonia in adults: A narrative review. Intensive Care Med. 2020; 46:888–906
Stasi C, Fallani S, Voller F, et al.: Treatment for COVID-19: An overview. Eur J Pharmacol. 2020; 889:173644
National Institutes of Health: COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/ . Accessed September 9, 2021
Payen D, Cravat M, Maadadi H, et al.: A longitudinal study of immune cells in severe COVID-19 patients. Front Immunol. 2020; 11:580250
Helms J, Tacquard C, Severac F, et al.; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis): High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020; 46:1089–1098
Lucchini A, Iozzo P, Bambi S: Nursing workload in the COVID-19 era. Intensive Crit Care Nurs. 2020; 61:102929
EARS: Antimicrobial Resistance in the EU/EEA (EARS-Net): Annual Epidemiological Report for 2019
Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al.: False-negative results of initial RT-PCR assays for COVID-19: A systematic review. PLoS One. 2020; 15:e0242958

Auteurs

Charles-Hervé Vacheron (CH)

PHE3ID, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, CNRS Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, France.
Pôle Santé Publique, Service de Biostatistique - Bioinformatique, Lyon, France.
Département d'Anesthésie Réanimation, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.

Alain Lepape (A)

PHE3ID, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, CNRS Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, France.
Hospices Civils de Lyon, Hôpital Henry Gabrielle, REA-REZO Surveillance Network, Infections & Antibiotic Resistance in ICU, F69230 Saint Genis Laval, Lyon, France.
Département d'Anesthésie Réanimation, Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France.

Anne Savey (A)

PHE3ID, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, CNRS Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, France.
Infection Prevention and Control, Hôpital Henry Gabrielle, Hospices Civils de Lyon, Lyon, France.

Anaïs Machut (A)

Hospices Civils de Lyon, Hôpital Henry Gabrielle, REA-REZO Surveillance Network, Infections & Antibiotic Resistance in ICU, F69230 Saint Genis Laval, Lyon, France.

Jean Francois Timsit (JF)

Médecine Intensive Reanimation Infectieuse APHP Hopital Bichat, IAME UMR1137, Université De Paris, F75018 Paris, France.

Philippe Vanhems (P)

PHE3ID, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, CNRS Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, France.
Unité d'hygiéne, Épidémiologie et prévention, Groupement hospitalier Centre, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Quoc Viet Le (QV)

Service de réanimation, Medipôle Lyon Villeurbanne, Villeurbanne, France.

Julia Egbeola (J)

Réanimation hôpital Foch, France.

Maelle Martin (M)

Médecine Intensive Réanimation, University Hospital Centre, Nantes, France.

Virginie Maxime (V)

Hôpital Poincare, 92380 Garches, France.

Paul-Simon Pugliesi (PS)

Centre hospitalier William Mirey, Réanimation polyvalente, Chalon sur Saône, France.

Delphine Maucort-Boulch (D)

Hôpital Henry Gabrielle, Villa Alice, 69230 Saint Genis-Laval, France.
Université de Lyon, F-69000, Lyon, France.
Université Lyon 1, F-69100, Villeurbanne, France.
Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et Bioinformatique, F-69003, Lyon, France.

Arnaud Friggeri (A)

PHE3ID, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, CNRS Unité Mixte de Recherche 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, France.
Département d'Anesthésie Réanimation, Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH